Zobrazeno 1 - 10
of 595
pro vyhledávání: '"M. González Barón"'
Autor:
R. Molina Villaverde, J. Feliu Batle, A. Villalba Yllan, A.M. Jiménez Gordo, B. San José Valiente, M. González Barón
Publikováno v:
Medicina y Seguridad del Trabajo, Vol 54, Iss 210, Pp 19-24 (2008)
Introducción. La actividad laboral en el cáncer es un aspecto psicosocial que ha recibido poca atención hasta el momento actual, a pesar de considerarse una dimensión de la calidad de vida para estos pacientes. Objetivos. La reinserción y adapta
Externí odkaz:
https://doaj.org/article/c77adac0d90f4a62ba201a074fc145ff
Publikováno v:
Revista de Medicina de la Universidad de Navarra. :97-101
La carcinomatosis meníngea (CM) es una complicación grave y habitualmente tardía en el curso evolutivo de algunos - 5 % - tumores sólidos extraneurales. Los adenocarcinomas de mama y de pulmón son actualmente el origen más frecuente. Presentamo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd234016dedd668143d76b0750c6ef69
https://doi.org/10.15581/021.6862
https://doi.org/10.15581/021.6862
Publikováno v:
Medicine - Programa de Formaci?n M?dica Continuada Acreditado. 9:4265-4269
PUNTOS CLAVE Tratamiento quirurgico. Dentro del cancer de pulmon, la variante de celula no pequena supone el 80% de casos * La cirugia es el tratamiento de eleccion de los casos de cancer de pulmon no microcitico que son resecables. Tratamiento medic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62eceea064a98ba357f02415f7d71da1
https://doi.org/10.1016/s0211-3449(06)74417-4
https://doi.org/10.1016/s0211-3449(06)74417-4
Autor:
F. Gómez Pastrana, E. Espinosa, Paloma Cejas, Brezo Martínez, J. J. Sánchez, M. González Barón, Andrés Redondo, J.A. Fresno Vara, Asunción Suárez, P. Zamora, David Hardisson, Francisco Calero
Publikováno v:
Journal of Clinical Oncology. 23:7278-7285
PurposeWe sought to reproduce with quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) the results obtained with a 70-gene expression profile that has been described previously in breast cancer.Patients and MethodsFrozen breast can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4923fd1ee3d9c8a1a746290a875ff0e
https://doi.org/10.1200/jco.2005.01.4746
https://doi.org/10.1200/jco.2005.01.4746
Autor:
Luc Dirix, Arnaud Roth, S. Van Belle, R. Morant, J-L. van Laethem, G. Gruia, Markus Borner, M. González Barón, E. Van Cutsem, Eric Joosens, Harry Bleiberg, D Sibaud
Publikováno v:
British Journal of Cancer, Vol. 92, No 6 (2005) pp. 1055-62
British Journal of Cancer
British Journal of Cancer, 92 (6
British Journal of Cancer
British Journal of Cancer, 92 (6
Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU). Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01841fe7e53d37d765b09741421b759d
https://doi.org/10.1038/sj.bjc.6602462
https://doi.org/10.1038/sj.bjc.6602462
Autor:
J. Belon, J. Janáriz, M. González Barón, M. de la Puente, Enrique Espinosa, J. Lizón, J. A. Moreno, P. Borrega, C. Madroñal, Ana María Moure Casas, Serafin Morales, J. A. Illarramendi, Ignacio Machengs, T. Checa, J. R. Mel
Publikováno v:
Cancer Chemotherapy and Pharmacology. 54:546-552
Epirubicin and docetaxel are two of the most active drugs against breast carcinoma. As the achievement of a pathological complete response (pCR) is important for survival of patients with locally advanced disease, we used both drugs as neoadjuvant ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1757436474779c9120339982fe2fd6d6
https://doi.org/10.1007/s00280-004-0830-1
https://doi.org/10.1007/s00280-004-0830-1
Autor:
F Carabantes, A Murias, Manuel Constenla, P Regueiro, G Perez-Manga, M Söderberg, J Castellanos, Anna Ruiz, Kenneth Villman, M. González Barón, J Casinello, N Batista, J Ahlgren
Publikováno v:
British Journal of Cancer
The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::277ca994200ed5ee34c0c1a19b3f1514
https://doi.org/10.1038/sj.bjc.6601784
https://doi.org/10.1038/sj.bjc.6601784
Autor:
C. Castañón, Luis Lopez-Gomez, M. González Barón, Carles Pericay, Antonieta Salud, Pilar Escudero, J. J. Sánchez, J M Rodríguez-García, M. Martinez, J. Feliu, M Sanz Martín, M R López de Tejada
Publikováno v:
British Journal of Cancer
To evaluate the efficacy and toxicity of irinotecan (CPT-11) in combination with raltitrexed as first-line treatment of advanced colorectal cancer (CRC). A total of 91 previously untreated patients with advanced CRC and measurable disease were enroll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff763dd9ac3bcd0cb011550508e76422
http://europepmc.org/articles/PMC2409728
http://europepmc.org/articles/PMC2409728
Publikováno v:
Lund University
Within the revolution of molecular biology in cancer, it should be pointed out the role of monoclonal antibodies clinically utilized as if they were "magic bullets". From the works of Kohler and Milstein in 1975 the evolution has been fast and its in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2391925e2f8e1b4ac15e0955cc4e2ea
https://doi.org/10.1016/s0014-2565(04)71571-4
https://doi.org/10.1016/s0014-2565(04)71571-4
Autor:
J. Dorta, R. Mel, M. González Barón, M. Bolaños, Eugenia Espinosa, L. López Gómez, J. Feliu, P. Borrega, Pilar Escudero, Javier de Castro, Sergio Vazquez-Estevez
Publikováno v:
Annals of Oncology. 13:1756-1762
Background: The objectives of this study were to evaluate the efficacy and toxicity of a fixed doserate infusion of gemcitabine associated with uracil/tegafur (UFT) in patients with advanced adenocarcinoma of the pancreas. Patients and methods: Forty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84364166a110b3930b0b8fb497a83d7b
https://doi.org/10.1093/annonc/mdf286
https://doi.org/10.1093/annonc/mdf286